Early interim CT is the strongest prognostic factor in metastatic gastrointestinal neuroendocrine carcinomas (GI-NEC): results from the French NECTAR study
Background Metastatic gastrointestinal neuroendocrine carcinoma (mGI-NEC) is known for its aggressive natural course with a short median overall survival (mOS). Currently, clinical tools guiding treatment strategy are lacking. We aimed to evaluate the prognostic impact of early depth of response (DpR). Patients and methods We conducted a retrospective study across 13 French centers. Consecutive patients with mGI-NEC treated with a platinum salt as first-line therapy between January 2010 and December 2023 were included. DpR was defined as the relative change in the sum of the largest diameters of target lesions on the first radiological assessment compared with baseline. Patients were stratified into 4 groups: (VGPR) (−100% to −60%); (PR) (−59% to −31%); (SD) (−30% to 0%); and (ITV) (0% or more). Multivariate Cox models, E-Values, bootstrap, and restrictive analyses were computed. Results Two hundred and twenty-nine patients with an mGI-NEC (colorectal for 28%, pancreatic for 24%) were included. mOS was 9.4 months. Seventy-five patients (33%) presented with ITV, 52 patients (23%) with SD, 70 patients (31%) with PR, and 32 patients (14%) with VGPR at first assessment (median of 2.1 months). mOS steadily decreased with the DpR. With SD as a reference, multivariate HR was 0.31 (0.19-0.50) for VGPR, 0.39 (0.27-0.58) for PR, and 2.17 (1.47-3.20) for ITV. Results of all sensitivity analyses were identical. Conclusion Early DpR was independently associated with OS and provided stronger prognostic discrimination than baseline factors. Prospective studies are warranted to determine whether DpR can guide risk-adapted treatment strategies.
Authors
- Fabien Moinard‐Butot (ORCID: https://orcid.org/0000-0002-5630-5220)
- Méher Ben Abdelghani (ORCID: https://orcid.org/0000-0002-9105-6346)
- Guillaume Cadiot (ORCID: https://orcid.org/0000-0002-2726-8715)
- Côme Lepage (ORCID: https://orcid.org/0000-0001-9211-4707)
- Vincent Hautefeuille (ORCID: https://orcid.org/0000-0003-2735-6448)
- M. Bolliet
- Marine Perrier (ORCID: https://orcid.org/0000-0002-4528-5471)
- M. Faure (ORCID: https://orcid.org/0000-0001-7554-0317)
- Émeric Boisteau (ORCID: https://orcid.org/0000-0003-1831-6145)
- Jean-Baptiste Barbe-Richaud (ORCID: https://orcid.org/0000-0002-1501-9391)
- M. Jary
- M. Müller
- A. Jenvrin
- M. Helyon
- J.-E. Kurtz
- D. Botsen
- M. Kroemer
- S. Husson
- J. Pinot
- C. Borg
Institutions
- Inserm (FR)
- Université Rennes 2 (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Hôpital Européen (FR)
- Délégation Centre-Est (FR)
- Hôpital Émile-Roux (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier de Mulhouse (FR)
- Centre Hospitalier de la Côte Basque (FR)
- Hôpital Privé Jean Mermo (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Établissement Français du Sang (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Institut Jean Godinot (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Université Marie et Louis Pasteur (FR)
- Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique (FR)
- Institut Strauss (FR)
- Université de Rennes (FR)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.esmogo.2026.100443
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00